Global aesthetic manufacturer Teoxane Laboratories has announced that the US Food and Drug Administration (FDA) has approved three of its dermal fillers.
RHA 2, RHA 3 and RHA 4 dermal fillers are now indicated by the Administration for the correction of moderate to severe dynamic facial wrinkles and folds in adults aged 22 years or older.
Teoxane’s founder and CEO Valerie Taupin said, “Since its inception in 2003, the foundations of the company have been based on integrated research and development. Today we are delighted with the news of the FDA approval of RHA 2, RHA 3 and RHA 4 for sale in the US market. This further reinforces our commitment to delivering science-based, high-quality HA dermal fillers to the global market.”